세계의 췌장 효소 대체 요법 시장 보고서(2025년)
Pancreatic Enzyme Replacement Global Market Report 2025
상품코드 : 1760669
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

췌장 효소 대체 요법 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 낭포성 섬유증의 소아 환자 수 증가, 희귀 질환에 대한 의료비 지출 증가, 효소 치료에 대한 보험 적용 범위 확대, 제약 회사의 전략적 파트너십 확대, 췌장 효소 치료에 대한 환자의 순응도 향상 등에 의해 촉진될 것으로 예상됩니다. 예측 기간의 주요 동향으로는 약물 전달 시스템의 발전, 효소 안정성 및 제형 혁신, 장용 코팅 기술의 발전, 새로운 췌장 효소 원료 연구, 개인 맞춤형 효소 치료 솔루션 개발 등이 있습니다.

위장 질환의 유병률이 증가함에 따라 향후 몇 년 동안 췌장 효소 대체 요법 시장이 성장할 것으로 예상됩니다. 위장 질환은 식도, 위, 장, 간, 췌장, 담낭 등 소화관에 영향을 미치는 질환입니다. 이러한 질환은 종종 복통, 복부 팽만감, 설사, 변비 등의 증상을 유발합니다. 위장관 질환의 증가세는 주로 가공식품 섭취 증가, 식이섬유 섭취 부족, 고지방 식단 등 불량한 식습관에 기인합니다. 이러한 요인은 장 건강을 손상시키고 위산 역류, 과민성 대장 증후군, 염증성 장 질환 등 질환을 유발할 수 있습니다. 췌장 효소 대체 요법은 영양소의 소화 및 흡수를 돕고, 영양 결핍, 복부 팽만, 지방 변과 같은 췌장 기능 저하와 관련된 증상을 완화합니다. 예를 들어, 2023년 12월 영국 기반 비영리 단체인 IBD 레지스트리는 염증성 장 질환(IBD) 환자가 5,300명을 초과했다고 보고했으며, 이는 2022년 대비 3,000명 이상 증가한 수치입니다. 이처럼 위장관 질환의 발생률 증가가 췌장 효소 대체요법 시장 확대에 기여하고 있습니다.

췌장 효소 대체 요법 시장의 기업들은 췌장 기능 저하 환자의 효소 안정성과 치료 효과를 개선하기 위해 지연 방출 캡슐과 같은 혁신적인 제형을 개발하고 있습니다. 이 캡슐은 소화관 내 특정 시간이나 위치에서 내용물을 방출하도록 설계되어 효소가 소장으로 전달되어 소화 과정을 돕습니다. 이 방법은 위산의 산성 환경으로부터 효소가 분해되는 것을 방지합니다. 예를 들어, 2025년 3월 말타에 본사를 두고 있는 제약 제조업체 아달보 리미티드(Adalvo Limited)는 외분비 췌장 기능 저하증(EPI) 환자의 효소 안정성과 치료 효과를 개선하기 위해 설계된 '판크레아틴 지연 방출 캡슐'을 출시했습니다. 이 캡슐은 위의 산성 환경을 우회해 소장에서 내용물을 방출하도록 특별히 설계되어, 효소가 분해되는 것을 방지합니다. 이 기술은 만성 췌장염, 낭성 섬유증, 췌장 절제술을 받은 환자들의 중요한 치료적 요구를 충족시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Pancreatic enzyme replacement is a treatment for individuals with insufficient pancreatic enzyme production. It uses synthetic enzymes, such as amylase, lipase, and protease, to assist in the digestion of carbohydrates, fats, and proteins. These enzymes are released into the small intestine, where they break down macronutrients into absorbable molecules, enhancing nutrient absorption and reducing symptoms such as malnutrition and weight loss in those with pancreatic insufficiency.

The primary forms of pancreatic enzyme replacement therapy include tablets, capsules, powders, and other forms. Pancreatic enzyme replacement tablets are oral medications designed to support digestion by providing essential enzymes to those with pancreatic insufficiency. The enzymes used in these therapies are sourced from various origins, including porcine-derived, microbial-derived, and recombinant-derived enzymes. These products are used to treat conditions such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer, among others. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other outlets, serving end users such as hospitals, clinics, and home healthcare environments.

The pancreatic enzyme replacement therapy market research report is one of a series of new reports from The Business Research Company that provides pancreatic enzyme replacement therapy market statistics, including pancreatic enzyme replacement therapy industry global market size, regional shares, competitors with a pancreatic enzyme replacement therapy market share, pancreatic enzyme replacement therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the pancreatic enzyme replacement therapy industry. This pancreatic enzyme replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic enzyme replacement market size has grown strongly in recent years. It will grow from $4.87 billion in 2024 to $5.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth during the historical period can be attributed to the rising prevalence of cystic fibrosis, an increase in chronic pancreatitis cases, growing awareness of pancreatic enzyme deficiency, advancements in diagnostic technologies, and continuous improvements in enzyme formulations.

The pancreatic enzyme replacement market size is expected to see strong growth in the next few years. It will grow to $7.08 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period is expected to be driven by the rising number of pediatric cases of cystic fibrosis, increased healthcare spending on rare diseases, broader insurance coverage for enzyme therapies, the expansion of strategic partnerships by pharmaceutical companies, and greater patient adherence to pancreatic enzyme treatments. Key trends for the forecast period include advancements in drug delivery systems, innovations in enzyme stability and formulations, progress in enteric coating technologies, research into novel pancreatic enzyme sources, and the development of personalized enzyme therapy solutions.

The increasing prevalence of gastrointestinal diseases is expected to drive the growth of the pancreatic enzyme replacement market in the coming years. Gastrointestinal diseases are conditions that affect the digestive tract, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder. These disorders often lead to symptoms such as abdominal pain, bloating, diarrhea, and constipation. The rise in gastrointestinal diseases is largely attributed to poor dietary habits, such as the increased consumption of processed foods, low fiber intake, and high-fat diets, which can disrupt gut health and contribute to conditions such as acid reflux, irritable bowel syndrome, and inflammatory bowel disease. Pancreatic enzyme replacement aids in the digestion and absorption of nutrients, thus alleviating symptoms such as malnutrition, bloating, and steatorrhea, which are commonly associated with pancreatic insufficiency. For example, in December 2023, the IBD Registry, a UK-based non-profit organization, reported that the number of individuals with inflammatory bowel disease (IBD) exceeded 5,300, marking an increase of over 3,000 members from 2022. As such, the growing incidence of gastrointestinal diseases is contributing to the expansion of the pancreatic enzyme replacement market.

Companies in the pancreatic enzyme replacement market are focusing on innovative formulations such as delayed-release capsules to improve enzyme stability and enhance therapeutic efficacy for patients with pancreatic insufficiency. These capsules are designed to release their contents at a specific time or location within the digestive tract, ensuring that the enzymes are delivered to the small intestine, where they can assist in digestion. This method also protects the enzymes from being degraded by the acidic environment of the stomach. For example, in March 2025, Adalvo Limited, a pharmaceutical manufacturing company based in Malta, introduced its Pancreatin Delayed-Release Capsules, designed to improve enzyme stability and therapeutic effectiveness for patients with exocrine pancreatic insufficiency (EPI). These capsules are specifically engineered to release their contents in the small intestine, bypassing the stomach's acidic environment, which would otherwise degrade the enzymes. This development addresses a critical need for patients with chronic pancreatitis, cystic fibrosis, and pancreatectomy.

In December 2023, Nestle Health Science S.A., a Switzerland-based nutritional science company, acquired CDX-7108 from Codexis Inc. for $45 million. This acquisition aims to advance the development and commercialization of CDX-7108, an experimental therapy designed to overcome the limitations of traditional pancreatic enzyme replacement therapy for exocrine pancreatic insufficiency (EPI). With this deal, Codexis will support Nestle Health Science in continuing clinical trials and bringing the therapy to market. Codexis Inc., a US-based protein engineering company, developed CDX-7108, a lipase variant designed to treat EPI through pancreatic enzyme replacement therapy.

Major players in the pancreatic enzyme replacement market are Johnson & Johnson, AbbVie Inc., Abbott Laboratories, Eli Lilly and Company, Viatris Inc., Nestle Health Science S.A., Eisai Co. Ltd., Chiesi Farmaceutici S.p.A., Now Health Group Inc., Codexis Inc., Anthera Pharmaceuticals Inc., AzurRx BioPharma Inc., Nordmark Arzneimittel GmbH & Co. KG, Alcresta Therapeutics Inc., ChemWerth Inc., Perseo Pharma AG, Cilian AG, Digestive Care Inc., Anagram Therapeutics Inc., and Entero Therapeutics Inc.

North America was the largest region in the pancreatic enzyme replacement market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pancreatic enzyme replacement report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pancreatic enzyme replacement market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic enzyme replacement market consists of revenues earned by entities by providing services such as enzyme supplementation, personalized treatment plans, patient education and support, and ongoing monitoring and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic enzyme replacement market also includes sales of creon, zenpep, pancreaze, ultresa, and pertzye. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Enzyme Replacement Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic enzyme replacement market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pancreatic enzyme replacement ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic enzyme replacement market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pancreatic Enzyme Replacement Market Characteristics

3. Pancreatic Enzyme Replacement Market Trends And Strategies

4. Pancreatic Enzyme Replacement Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pancreatic Enzyme Replacement Growth Analysis And Strategic Analysis Framework

6. Pancreatic Enzyme Replacement Market Segmentation

7. Pancreatic Enzyme Replacement Market Regional And Country Analysis

8. Asia-Pacific Pancreatic Enzyme Replacement Market

9. China Pancreatic Enzyme Replacement Market

10. India Pancreatic Enzyme Replacement Market

11. Japan Pancreatic Enzyme Replacement Market

12. Australia Pancreatic Enzyme Replacement Market

13. Indonesia Pancreatic Enzyme Replacement Market

14. South Korea Pancreatic Enzyme Replacement Market

15. Western Europe Pancreatic Enzyme Replacement Market

16. UK Pancreatic Enzyme Replacement Market

17. Germany Pancreatic Enzyme Replacement Market

18. France Pancreatic Enzyme Replacement Market

19. Italy Pancreatic Enzyme Replacement Market

20. Spain Pancreatic Enzyme Replacement Market

21. Eastern Europe Pancreatic Enzyme Replacement Market

22. Russia Pancreatic Enzyme Replacement Market

23. North America Pancreatic Enzyme Replacement Market

24. USA Pancreatic Enzyme Replacement Market

25. Canada Pancreatic Enzyme Replacement Market

26. South America Pancreatic Enzyme Replacement Market

27. Brazil Pancreatic Enzyme Replacement Market

28. Middle East Pancreatic Enzyme Replacement Market

29. Africa Pancreatic Enzyme Replacement Market

30. Pancreatic Enzyme Replacement Market Competitive Landscape And Company Profiles

31. Pancreatic Enzyme Replacement Market Other Major And Innovative Companies

32. Global Pancreatic Enzyme Replacement Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pancreatic Enzyme Replacement Market

34. Recent Developments In The Pancreatic Enzyme Replacement Market

35. Pancreatic Enzyme Replacement Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기